The role of tamoxifen in reducing bicalutamide-induced gynaecomastia and breast pain

BJU International

Volumn 99, Issue 2, 2007, Pages 243-244

  Nuttall, Martin C ^a   Harris, James P ^a   Dawkins, Guy P C ^a  

^a Bromley Hospitals NHS Trust   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANDROGEN; ANTIANDROGEN; BICALUTAMIDE; ESTROGEN; NOVALDEX D; PLACEBO; PROSTATE SPECIFIC ANTIGEN; TAMOXIFEN; TESTOSTERONE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; BREAST; CANCER HORMONE THERAPY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG COST; DRUG EFFICACY; DRUG WITHDRAWAL; GYNECOMASTIA; HORMONE ACTION; HUMAN; HYPOGONADISM; INTERMETHOD COMPARISON; IRRADIATION; MASTALGIA; MONOTHERAPY; NOTE; PRIORITY JOURNAL; PROPHYLAXIS; PROSTATE CANCER; SEXUALITY; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANDROGEN ANTAGONISTS; ANILIDES; ANTINEOPLASTIC AGENTS, HORMONAL; GYNECOMASTIA; HUMANS; MALE; PAIN; PROSTATIC NEOPLASMS; TAMOXIFEN; TOSYL COMPOUNDS; TREATMENT OUTCOME;

EID: 33846256731     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2006.06552.x     Document Type: Note

References (11)

1. Dobs A, Darkes MJ. Incidence and management of gynaecomastia in men treated for prostate cancer. J Urol 2005; 174: 1737-42
2. See WA, Wirth M, McLeod DG et al. Bicalutamide as immediate therapy, either alone or as adjunct to standard care of patients with localised or locally advanced prostate cancer: first analysis of the Early Prostate Cancer Program. J Urol 2002; 168: 429-35
3. Wirth MP, See WA, McLeod DG, Iverson P, Morris T, Carroll K; Casodex Early Prostate Cancer Trialists' Group. Bicalutamide 150mg in addition to standard care in patients with localized or locally advanced prostate cancer: results from the second analysis of early prostate cancer program at median followup of 5.4 years. J Urol 2004; 172: 1865-70
4. Widmark A, Fossa SD, Lundmo P et al. Does prophylactic breast irradiation prevent antiandrogen-induced gynaecomastia? Evaluation of 253 patients in the randomized Scandinavian trial SPCG-7/SFUO-3. Urology 2003; 61: 145-51
5. McLeod DG, Iversen P. Gynecomastia in patients with prostate cancer: a review of treatment options. Urology 2000; 56: 713-20
6. Staiman VR, Lowe FC. Tamoxifen for flutamide/finasteride-induced gynecomastia. Urology, 1997; 50: 929-33
7. Boccardo F, Rubagotti A, Battaglia M et al. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol 2005; 23: 808-15
8. Saltzstein D, Sieber P, Morris T, Gallo J. Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomised endocrinologic and clinical studies with tamoxifen and anastrozole. Prostate Cancer Prostatic Dis 2005; 8: 75-83
9. Di Lorenzo G, Perdona S, De Placido S et al. Gynecomastia and breast pain induced by adjuvant therapy with bicalutamide after radical prostatectomy in patients prostate cancer: the role of tamoxifen and radiotherapy. J Urol 2005; 174: 2197-203
10. British National Formulary. Available at: http://www.bnf.org/bnf/. Accessed August 2006
11. Ochel HJ. A proposal for the repositioning of prophylactic breast radiotherapy of prostate cancer patients. Future Oncol 2005; 1: 625-9